Treatment with a GnRH analogue: effects on hemostatic risk factors for thrombo-embolic disease.

What Was Tested

The paper reports a study of Goserelin, published as a controlled clinical trial.

Steroid hormones, especially estrogens, are known to affect hemostatic risk factors for thromboembolism, cardiovascular disease, and stroke.

The researchers examined these risk factors during depression of the serum estradiol concentration by a GnRH analogue.

Who Took Part

According to the abstract, 20 women were involved.

The age groups tagged for this paper are adults and middle-aged adults, women only.

Blood samples were collected during and after treatment and in a control group.

In ten patients a blood sample was also drawn before treatment.

How the Study Was Run

Measurements were made of serum estradiol, and the plasma concentrations of tissue-type plasminogen activator (t-PA) antigen, plasminogen activator inhibitor (PAI-1) antigen, antithrombin III (AT III) and protein C activity, factor VII (FVII) antigen, and fibrinogen.

Outpatient clinics at the Departments of Obstetrics and Gynecology at two university hospitals in southern Sweden.

Twenty-seven women with endometriosis were consecutively included.

A control group comprised 20 women with normal menstrual cycles.

What Was Measured

The subject headings attached to it are Antithrombin III, Endometriosis, Estradiol, Factor VII, Fibrinogen, Goserelin and Hemostasis.

What This Means in Plain Language

This is a controlled clinical trial of Goserelin in 20 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1994 (International journal of fertility and menopausal studies), a journal based in United States.

More context: the related Goserelin library page, all human trials.